Investment Analysts’ Updated EPS Estimates for September 20th (ABEO, ACET, ACHC, ACN, ADMA, AGIO, ALGS, ANGO, AWK, CAPR)

Investment Analysts’ updated eps estimates for Friday, September 20th:

Abeona Therapeutics (NASDAQ:ABEO) had its overweight rating reiterated by analysts at Cantor Fitzgerald. The firm currently has a $18.00 price target on the stock.

Adicet Bio (NASDAQ:ACET) had its outperform rating reaffirmed by analysts at Wedbush. Wedbush currently has a $5.00 target price on the stock.

Acadia Healthcare (NASDAQ:ACHC) had its outperform rating reissued by analysts at Royal Bank of Canada. They currently have a $94.00 target price on the stock.

Accenture (NYSE:ACN) had its neutral rating reissued by analysts at Piper Sandler Companies. Piper Sandler Companies currently has a $329.00 price target on the stock.

ADMA Biologics (NASDAQ:ADMA) had its overweight rating reiterated by analysts at Cantor Fitzgerald. They currently have a $20.00 price target on the stock.

Agios Pharmaceuticals (NASDAQ:AGIO) had its overweight rating reiterated by analysts at Cantor Fitzgerald.

Aligos Therapeutics (NASDAQ:ALGS) had its buy rating reaffirmed by analysts at HC Wainwright. The firm currently has a $75.00 target price on the stock.

AngioDynamics (NASDAQ:ANGO) had its buy rating reiterated by analysts at HC Wainwright. They currently have a $14.00 price target on the stock.

American Water Works (NYSE:AWK) had its underperform rating reiterated by analysts at Bank of America Co.. Bank of America Co. currently has a $140.00 target price on the stock.

Capricor Therapeutics (NASDAQ:CAPR) had its overweight rating reissued by analysts at Cantor Fitzgerald. The firm currently has a $8.00 target price on the stock.

Codexis (NASDAQ:CDXS) had its overweight rating reiterated by analysts at Cantor Fitzgerald. They currently have a $11.00 target price on the stock.

Chord Energy (NASDAQ:CHRD) had its outperform rating reaffirmed by analysts at Royal Bank of Canada. The firm currently has a $200.00 price target on the stock.

Centene (NYSE:CNC) had its overweight rating reissued by analysts at Cantor Fitzgerald. Cantor Fitzgerald currently has a $90.00 price target on the stock.

Concentrix (NASDAQ:CNXC) had its outperform rating reaffirmed by analysts at Barrington Research. The firm currently has a $84.00 target price on the stock.

Corbus Pharmaceuticals (NASDAQ:CRBP) had its outperform rating reiterated by analysts at Mizuho. Mizuho currently has a $74.00 target price on the stock.

Corbus Pharmaceuticals (NASDAQ:CRBP) had its outperform rating reissued by analysts at Royal Bank of Canada. Royal Bank of Canada currently has a $82.00 price target on the stock.

Salesforce (NYSE:CRM) had its buy rating reiterated by analysts at Needham & Company LLC. The firm currently has a $345.00 target price on the stock.

Cytokinetics (NASDAQ:CYTK) had its buy rating reissued by analysts at HC Wainwright. They currently have a $90.00 target price on the stock.

DocGo (NASDAQ:DCGO) had its overweight rating reissued by analysts at Cantor Fitzgerald. The firm currently has a $5.00 target price on the stock.

Digihost Technology (NASDAQ:DGHI) had its buy rating reissued by analysts at HC Wainwright. They currently have a $2.50 target price on the stock.

Dolby Laboratories (NYSE:DLB) had its outperform rating reaffirmed by analysts at Barrington Research. The firm currently has a $100.00 target price on the stock.

Domino’s Pizza (NYSE:DPZ) had its hold rating reaffirmed by analysts at Loop Capital. They currently have a $419.00 price target on the stock.

Elevance Health (NYSE:ELV) had its overweight rating reiterated by analysts at Cantor Fitzgerald. They currently have a $600.00 target price on the stock.

89bio (NASDAQ:ETNB) had its overweight rating reiterated by analysts at Cantor Fitzgerald. Cantor Fitzgerald currently has a $29.00 target price on the stock.

Evaxion Biotech A/S (NASDAQ:EVAX) had its buy rating reaffirmed by analysts at HC Wainwright. The firm currently has a $14.00 target price on the stock.

Exelixis (NASDAQ:EXEL) had its market outperform rating reaffirmed by analysts at JMP Securities. JMP Securities currently has a $29.00 target price on the stock.

FedEx (NYSE:FDX) had its overweight rating reissued by analysts at Stephens. Stephens currently has a $350.00 price target on the stock.

Amicus Therapeutics (NASDAQ:FOLD) had its overweight rating reaffirmed by analysts at Cantor Fitzgerald. The firm currently has a $20.00 price target on the stock.

Genmab A/S (NASDAQ:GMAB) had its buy rating reiterated by analysts at HC Wainwright. The firm currently has a $50.00 price target on the stock.

Gryphon Digital Mining (NASDAQ:GRYP) had its neutral rating reissued by analysts at HC Wainwright.

Health Catalyst (NASDAQ:HCAT) had its overweight rating reiterated by analysts at Cantor Fitzgerald. Cantor Fitzgerald currently has a $16.00 target price on the stock.

HealthEquity (NASDAQ:HQY) had its outperform rating reaffirmed by analysts at Barrington Research. They currently have a $105.00 price target on the stock.

Henry Schein (NASDAQ:HSIC) had its outperform rating reissued by analysts at Barrington Research. The firm currently has a $82.00 target price on the stock.

Heidrick & Struggles International (NASDAQ:HSII) had its outperform rating reissued by analysts at Barrington Research. They currently have a $44.00 target price on the stock.

Humana (NYSE:HUM) had its neutral rating reiterated by analysts at Cantor Fitzgerald. Cantor Fitzgerald currently has a $395.00 target price on the stock.

Humacyte (NASDAQ:HUMA) had its overweight rating reissued by analysts at Cantor Fitzgerald. Cantor Fitzgerald currently has a $13.00 target price on the stock.

Hut 8 (NASDAQ:HUT) had its buy rating reiterated by analysts at HC Wainwright. They currently have a $13.50 target price on the stock.

ICF International (NASDAQ:ICFI) had its outperform rating reaffirmed by analysts at Barrington Research. They currently have a $174.00 target price on the stock.

Disc Medicine (NASDAQ:IRON) had its overweight rating reiterated by analysts at Cantor Fitzgerald. Cantor Fitzgerald currently has a $85.00 price target on the stock.

Johnson & Johnson (NYSE:JNJ) had its outperform rating reissued by analysts at Royal Bank of Canada. Royal Bank of Canada currently has a $175.00 target price on the stock.

Kadant (NYSE:KAI) had its outperform rating reaffirmed by analysts at Barrington Research. The firm currently has a $360.00 price target on the stock.

OPENLANE (NYSE:KAR) had its outperform rating reiterated by analysts at Barrington Research. They currently have a $25.00 target price on the stock.

Lennar (NYSE:LEN) had its neutral rating reissued by analysts at Wedbush. Wedbush currently has a $144.00 target price on the stock.

LifeMD (NASDAQ:LFMD) had its overweight rating reissued by analysts at Cantor Fitzgerald. They currently have a $15.00 target price on the stock.

Lincoln Educational Services (NASDAQ:LINC) had its outperform rating reaffirmed by analysts at Barrington Research. The firm currently has a $16.00 target price on the stock.

LeMaitre Vascular (NASDAQ:LMAT) had its outperform rating reissued by analysts at Barrington Research. Barrington Research currently has a $92.00 price target on the stock.

Grand Canyon Education (NASDAQ:LOPE) had its outperform rating reaffirmed by analysts at Barrington Research. Barrington Research currently has a $165.00 price target on the stock.

LightPath Technologies (NASDAQ:LPTH) had its buy rating reaffirmed by analysts at HC Wainwright. HC Wainwright currently has a $3.00 target price on the stock.

Stride (NYSE:LRN) had its outperform rating reaffirmed by analysts at Barrington Research. Barrington Research currently has a $90.00 price target on the stock.

LTC Properties (NYSE:LTC) had its outperform rating reiterated by analysts at Wedbush. The firm currently has a $40.00 price target on the stock.

Marcus (NYSE:MCS) had its outperform rating reissued by analysts at Barrington Research. Barrington Research currently has a $20.00 price target on the stock.

Matador Resources (NYSE:MTDR) had its outperform rating reiterated by analysts at Royal Bank of Canada. They currently have a $75.00 price target on the stock.

NIKE (NYSE:NKE) had its buy rating reissued by analysts at Deutsche Bank Aktiengesellschaft. The firm currently has a $92.00 target price on the stock.

NIKE (NYSE:NKE) had its equal weight rating reissued by analysts at Morgan Stanley. They currently have a $79.00 target price on the stock.

Insight Enterprises (NASDAQ:NSIT) had its outperform rating reaffirmed by analysts at Barrington Research. The firm currently has a $225.00 target price on the stock.

Nutrien (NYSE:NTR) had its outperform rating reiterated by analysts at Royal Bank of Canada. Royal Bank of Canada currently has a $60.00 price target on the stock.

Ollie’s Bargain Outlet (NASDAQ:OLLI) had its buy rating reaffirmed by analysts at Loop Capital. They currently have a $110.00 price target on the stock.

OPKO Health (NASDAQ:OPK) had its outperform rating reiterated by analysts at Barrington Research. The firm currently has a $2.25 price target on the stock.

Proficient Auto Logistics (NASDAQ:PAL) had its outperform rating reaffirmed by analysts at Barrington Research. Barrington Research currently has a $22.00 target price on the stock.

Planet Labs PBC (NYSE:PL) had its market outperform rating reissued by analysts at JMP Securities. The firm currently has a $4.00 target price on the stock.

Perdoceo Education (NASDAQ:PRDO) had its outperform rating reaffirmed by analysts at Barrington Research. The firm currently has a $30.00 target price on the stock.

Quad/Graphics (NYSE:QUAD) had its outperform rating reissued by analysts at Barrington Research. The firm currently has a $8.50 price target on the stock.

Rezolute (NASDAQ:RZLT) had its market outperform rating reiterated by analysts at JMP Securities. The firm currently has a $7.00 target price on the stock.

Snap-on (NYSE:SNA) had its outperform rating reaffirmed by analysts at Barrington Research. The firm currently has a $325.00 target price on the stock.

Sarepta Therapeutics (NASDAQ:SRPT) had its neutral rating reiterated by analysts at Cantor Fitzgerald. Cantor Fitzgerald currently has a $152.00 target price on the stock.

Interface (NASDAQ:TILE) had its outperform rating reissued by analysts at Barrington Research. Barrington Research currently has a $22.00 target price on the stock.

Thermo Fisher Scientific (NYSE:TMO) had its outperform rating reissued by analysts at Royal Bank of Canada. The firm currently has a $767.00 price target on the stock.

Union Pacific (NYSE:UNP) had its outperform rating reaffirmed by analysts at Royal Bank of Canada. The firm currently has a $275.00 target price on the stock.

U.S. Physical Therapy (NYSE:USPH) had its outperform rating reaffirmed by analysts at Barrington Research. They currently have a $108.00 target price on the stock.

Essential Utilities (NYSE:WTRG) had its buy rating reaffirmed by analysts at Bank of America Co.. Bank of America Co. currently has a $45.00 price target on the stock.

DENTSPLY SIRONA (NASDAQ:XRAY) had its outperform rating reiterated by analysts at Barrington Research. Barrington Research currently has a $36.00 price target on the stock.